Perez et al., 2014 - Google Patents
A pilot study on the potential of RNA-associated to urinary vesicles as a suitable non-invasive source for diagnostic purposes in bladder cancerPerez et al., 2014
View HTML- Document ID
- 2827700421366684376
- Author
- Perez A
- Loizaga A
- Arceo R
- Lacasa I
- Rabade A
- Zorroza K
- Mosen-Ansorena D
- Gonzalez E
- Aransay A
- Falcon-Perez J
- Unda-Urzaiz M
- Royo F
- Publication year
- Publication venue
- Cancers
External Links
Snippet
Bladder cancer is one of the most common cancers and, together with prostate carcinoma, accounts for the majority of the malignancies of the genitourinary tract. Since prognosis ameliorates with early detection, it will be beneficial to have a repertoire of diagnostic …
- 206010005003 Bladder cancer 0 title abstract description 39
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/01—Social networking
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Perez et al. | A pilot study on the potential of RNA-associated to urinary vesicles as a suitable non-invasive source for diagnostic purposes in bladder cancer | |
Ulivi et al. | Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC | |
Zhang et al. | Combined elevation of microRNA-196a and microRNA-196b in sera predicts unfavorable prognosis in patients with osteosarcomas | |
Nunes et al. | Subtyping lung cancer using DNA methylation in liquid biopsies | |
Deng et al. | Long non-coding RNA as potential biomarker for prostate cancer: is it making a difference? | |
Shi et al. | Frequent gene amplification predicts poor prognosis in gastric cancer | |
Ohyashiki et al. | Downregulation of plasma miR-215 in chronic myeloid leukemia patients with successful discontinuation of imatinib | |
Ranković et al. | Epithelial-mesenchymal transition-related microRNAs and their target genes in colorectal cancerogenesis | |
Keup et al. | Cell-free DNA variant sequencing using CTC-depleted blood for comprehensive liquid biopsy testing in metastatic breast cancer | |
Schmidt et al. | A pilot study to non-invasively track PIK3CA mutation in head and neck cancer | |
Caramés et al. | MicroRNA-31 emerges as a predictive biomarker of pathological response and outcome in locally advanced rectal cancer | |
Carrasco et al. | Cell-free DNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer | |
Yu et al. | Cell-free RNA content in peripheral blood as potential biomarkers for detecting circulating tumor cells in non-small cell lung carcinoma | |
Dama et al. | Deciphering the molecular profile of lung cancer: new strategies for the early detection and prognostic stratification | |
Han et al. | Promoter methylation of cancer stem cell surface markers as an epigenetic biomarker for prognosis of oral squamous cell carcinoma | |
Cheng et al. | Systemic investigation identifying salivary miR-196b as a promising biomarker for early detection of head-neck cancer and oral precancer lesions | |
Nitusca et al. | Long noncoding RNA NEAT1 as a potential candidate biomarker for prostate cancer | |
Bertol et al. | BRAF, TERT and HLA-G status in the papillary thyroid carcinoma: a clinicopathological association study | |
Jeong et al. | Methylation of the NT5E gene is associated with poor prognostic factors in breast cancer | |
Liu et al. | Clinicopathologic features and molecular biomarkers as predictors of epidermal growth factor receptor gene mutation in non-small cell lung cancer patients | |
Huth et al. | Molecular diagnostic applications in colorectal cancer | |
Goričar et al. | Extracellular Vesicle Enriched miR-625-3p Is Associated with Survival of Malignant Mesothelioma Patients | |
Garajei et al. | Evaluation of the Expression Levels of miR-21-5p and miR-429 Genes in Biopsy Samples from Patients with Oral Squamous Cell Carcinoma | |
Markou et al. | The effect of genomic DNA contamination on the detection of circulating long non-coding RNAs: The Paradigm of MALAT1 | |
Zafeiriadou et al. | Metabolism-related gene expression in circulating tumor cells from patients with early stage non-small cell lung cancer |